OncoImmunology · 2021 · 15 citations · 46 references
Life SciencesMolecular BiologyOncologyChromatin BiologyEpigeneticsGene ExpressionCancer EpigeneticsCancer EpigenomicsChromatinEpigenetic Regulation In CancerHistone ModificationsHistone ProteinsAcute Myeloid Leukemia BiologyBromodomain InhibitionBromodomain ProteinsCancer Epigenetic BiomarkersEpigenetic ReadersEpigenomic AlterationsP-tefb RegulationRna Polymerase Ii Regulation
levels, myelodysplastic-derived AML, and del5q, the two latter being associated with poor prognosis. Our data show that BRD4 is a positive regulator of the pro-tumorigenic molecule B7-H6 and that the blockage of the B7-H6 is a potential therapeutic target for the treatment of AML.
46
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations
CBP/p300 in cell growth, transformation, and development
Richard H. Goodman, Sarah M. Smolik · Genes & Development · 2000 · 1.8K citations · Full text
Structure and ligand of a histone acetyltransferase bromodomain
Christophe Dhalluin, Justin E. Carlson, Lei Zeng et al. · Nature · 1999 · 1.7K citations